Menu Search
Equities

Insulet Corp

PODD:NSQ

Insulet Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)262.15
  • Today's Change0.150 / 0.06%
  • Shares traded148.07k
  • 1 Year change+40.71%
  • Beta1.2014
Data delayed at least 15 minutes, as of Nov 22 2024 17:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Insulet Corp grew revenues 30.02% from 1.31bn to 1.70bn while net income improved 4,384.78% from 4.60m to 206.30m.
Gross margin69.36%
Net profit margin21.22%
Operating margin15.42%
Return on assets15.32%
Return on equity48.79%
Return on investment18.56%
More ▼

Cash flow in USDView more

In 2023, Insulet Corp did not generate a significant amount of cash. However, the company earned 145.70m from its operations for a Cash Flow Margin of 8.59%. In addition the company used 119.40m on investing activities and also paid 13.60m in financing cash flows.
Cash flow per share6.53
Price/Cash flow per share36.83
Book value per share15.94
Tangible book value per share13.78
More ▼

Balance sheet in USDView more

Insulet Corp has a Debt to Total Capital ratio of 55.57%, a lower figure than the previous year's 225.61%.
Current ratio3.68
Quick ratio2.80
Total debt/total equity1.25
Total debt/total capital0.5557
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 4,372.60%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years)122.51
EPS (TTM) vs
TTM 1 year ago		237.38
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.